BioRestorative Therapies, Inc.
BRTX
$2.74
-$0.06-2.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -8.47% | -10.30% | 1.70% | 247.62% | 161.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.47% | -10.30% | 1.70% | 247.62% | 161.54% |
| Cost of Revenue | -8.41% | -15.00% | 3.24% | 409.23% | -- |
| Gross Profit | -8.47% | -9.95% | 1.59% | 241.35% | 140.87% |
| SG&A Expenses | -3.29% | -5.95% | -22.79% | -34.94% | -45.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.33% | 33.88% | 19.52% | 4.72% | -7.71% |
| Operating Income | -16.09% | -35.41% | -20.07% | -1.45% | 9.58% |
| Income Before Tax | 8.59% | -58.61% | -31.34% | -183.12% | -121.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.59% | -58.61% | -31.34% | -183.12% | -121.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.59% | -58.61% | -31.34% | -183.12% | -121.20% |
| EBIT | -16.09% | -35.41% | -20.07% | -1.45% | 9.58% |
| EBITDA | -16.25% | -35.82% | -20.16% | -1.25% | 9.91% |
| EPS Basic | 26.03% | -37.79% | -1.53% | -360.55% | -17.59% |
| Normalized Basic EPS | 13.67% | -68.20% | 12.94% | -284.66% | -0.75% |
| EPS Diluted | 26.03% | -37.79% | -1.53% | -355.32% | -17.21% |
| Normalized Diluted EPS | 13.67% | -68.20% | 12.94% | -284.66% | -0.75% |
| Average Basic Shares Outstanding | 38.51% | 15.84% | 24.40% | 38.64% | 65.16% |
| Average Diluted Shares Outstanding | 38.51% | 15.84% | 24.40% | 38.64% | 65.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |